CompletedNCT00821600

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

Medication studyAges 18–55United States

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Listed locations: Cerritos and 2 more locationsSee all locations and recruitment
Study phase: Phase 1

Study clarity

Study start dateDecember 2008

Recruitment status: Completed
Enrollment listed in the registry: 24
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Drug
Study phase: Phase 1
Locations: United States
Age range: From 18 Years to 55 Years
Official registry ID: NCT00821600
Official title: Show the full official title
Single-Dose, Open-Label Pilot Study to Explore the Pharmacokinetics, Safety and Tolerability of a Gluteal Intramuscular Injection of a 4-Week Long-Acting Injectable Formulation of Risperidone in Patients With Chronic Stable Schizophrenia

Completed

Cerritos · Santa Ana · Atlanta

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including risperidone IR and LAI formulation.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.